Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin + cytarabine liposome (Jazz Pharmaceuticals plc, b73b5f)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
daunorubicin + cytarabine liposome (JZP351, CPX-351, Vyxeos) is a dual-drug liposomal formulation encapsulating daunorubicin and cytarabine at a fixed 1:5 molar ratio, designed to maintain synergistic drug exposure and improve delivery to leukemia cells. This formulation is approved for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. The liposomal encapsulation enhances preferential delivery to malignant cells, provides sustained drug exposure, and is associated with improved remission rates and overall survival compared to conventional cytarabine plus daunorubicin ("7+3") regimens in high-risk AML populations. Key features include reduced gastrointestinal and cardiac toxicities compared to conventional formulations. The mechanism involves inhibition of DNA synthesis and function in leukemia cells through the combined actions of a nucleoside analog (cytarabine) and a topoisomerase II inhibitor (daunorubicin)[1][2][3][7].
- Brand names
- VyxeosVyxeos Liposomal
- Other names
- liposomal daunorubicin + cytarabineL-DA
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin + cytarabine liposome (Jazz Pharmaceuticals plc, b73b5f).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin + cytarabine liposome (Jazz Pharmaceuticals plc, b73b5f).